153 related articles for article (PubMed ID: 38771511)
1. Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni.
Mohammad OS; Hussein HM; Abdel-Sayed SW; Mohamed GA; Shehata MAS
Parasitol Res; 2024 May; 123(5):215. PubMed ID: 38771511
[TBL] [Abstract][Full Text] [Related]
2. Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz.
Morsy GH
J Egypt Soc Parasitol; 2009 Aug; 39(2):687-701. PubMed ID: 19795775
[TBL] [Abstract][Full Text] [Related]
3. Schistosomicidal and hepatoprotective activity of gamma-aminobutyric acid (GABA) alone or combined with praziquantel against Schistosoma mansoni infection in murine model.
Fahmy AM; William S; Hegab A; Tm D
Exp Parasitol; 2022 Jul; 238():108260. PubMed ID: 35447136
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni.
el-Lakkany NM; el-Din SH; Sabra AN; Hammam OA
Mem Inst Oswaldo Cruz; 2011 Nov; 106(7):814-22. PubMed ID: 22124553
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the potential therapeutic effects of omeprazole in Schistosoma mansoni infected mice.
Ellakany AR; Elgendy DI; Alshenawy HA; Abdel Ghaffar AE
Parasitol Res; 2019 Dec; 118(12):3399-3408. PubMed ID: 31655904
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni.
Eissa MM; El-Azzouni MZ; El-Khordagui LK; Abdel Bary A; El-Moslemany RM; Abdel Salam SA
Acta Trop; 2020 Dec; 212():105714. PubMed ID: 32950482
[TBL] [Abstract][Full Text] [Related]
7. Itraconazole, a cytochrome P450 inhibitor, enhanced the efficacy of praziquantel against Schistosoma mansoni infection and alleviated liver injury in mice.
Sabra AA; Salem MB; William S; Hammam OA; El-Lakkany NM
Exp Parasitol; 2022 Aug; 239():108293. PubMed ID: 35667394
[TBL] [Abstract][Full Text] [Related]
8. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection.
Radwan A; El-Lakkany NM; William S; El-Feky GS; Al-Shorbagy MY; Saleh S; Botros S
Parasit Vectors; 2019 Jun; 12(1):304. PubMed ID: 31208446
[TBL] [Abstract][Full Text] [Related]
9. Insulin growth factor inhibitor as a potential new anti-schistosoma drug: An in vivo experimental study.
Elhenawy AA; Ashour RH; Nabih N; Shalaby NM; El-Karef AA; Abou-El-Wafa HS
Biomed Pharmacother; 2017 Nov; 95():1346-1358. PubMed ID: 28946182
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the therapeutic efficacy of praziquantel in murine Schistosomiasis mansoni using silica nanocarrier.
Tawfeek GM; Baki MHA; Ibrahim AN; Mostafa MAH; Fathy MM; Diab MSEDM
Parasitol Res; 2019 Dec; 118(12):3519-3533. PubMed ID: 31673833
[TBL] [Abstract][Full Text] [Related]
11. Schistosoma mansoni: In vivo evaluation of Phyllanthus amarus hexanic and ethanolic extracts.
de Oliveira CNF; Frezza TF; Garcia VL; Figueira GM; Mendes TMF; Allegretti SM
Exp Parasitol; 2017 Dec; 183():56-63. PubMed ID: 29074138
[TBL] [Abstract][Full Text] [Related]
12. Praziquantel efficacy in mice infected with PZQ non-susceptible S. mansoni isolate treated with artemether: parasitological, biochemical and immunohistochemical assessment.
Botros SS; Hammam O; Mahmoud M; Bergquist R
APMIS; 2010 Sep; 118(9):692-702. PubMed ID: 20718722
[TBL] [Abstract][Full Text] [Related]
13. Overview on cysteine protease inhibitors as chemotherapy for Schistosomiasis mansoni in mice and also its effect on the parasitological and immunological profile.
Farid A; Malek AA; Rabie I; Helmy A; El Amir AM
Pak J Biol Sci; 2013 Dec; 16(24):1849-61. PubMed ID: 24517000
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of alpha lipoic acid combined with praziquantel on liver fibrosis induced by Schistosoma mansoni challenged mice.
Abdel-Hafeez EH; Ahmad AK; Abdulla AM; Aabdel-Wahab S; Mosalem FA
Parasitol Res; 2012 Aug; 111(2):577-86. PubMed ID: 22398831
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni.
Lotfy WM; Hishmat MG; El Nashar AS; Abu El Einin HM
Pharm Biol; 2015 Aug; 53(8):1214-9. PubMed ID: 25609146
[TBL] [Abstract][Full Text] [Related]
16. Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay.
Frezza TF; Gremião MP; Zanotti-Magalhães EM; Magalhães LA; de Souza AL; Allegretti SM
Acta Trop; 2013 Oct; 128(1):70-5. PubMed ID: 23811113
[TBL] [Abstract][Full Text] [Related]
17. Parasitological and histopathological studies to the effect of aqueous extract of Moringa oleifera Lam. leaves combined with praziquantel therapy in modulating the liver and spleen damage induced by Schistosoma mansoni to male mice.
Saad El-Din MI; Gad El-Hak HN; Ghobashy MA; Elrayess RA
Environ Sci Pollut Res Int; 2023 Feb; 30(6):15548-15560. PubMed ID: 36169837
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice.
Tanaka M; Ohmae H; Utsunomiya H; Nara T; Irie Y; Yasuraoka K
Am J Trop Med Hyg; 1989 Aug; 41(2):198-203. PubMed ID: 2505624
[TBL] [Abstract][Full Text] [Related]
19. Impact of treatment with a Protein Tyrosine Kinase Inhibitor (Genistein) on acute and chronic experimental Schistosoma mansoni infection.
Sobhy MMK; Mahmoud SS; El-Sayed SH; Rizk EMA; Raafat A; Negm MSI
Exp Parasitol; 2018 Feb; 185():115-123. PubMed ID: 29331278
[TBL] [Abstract][Full Text] [Related]
20. Parasitological, hematological and ultrastructural study of the effect of COX-2 inhibitor, pyocyanin pigment and praziquantel, on S. mansoni infected mice.
Mohamed AH; Ezz El-Din N; Fahmy ZH; El-Shennawy AM; Hassan E
J Egypt Soc Parasitol; 2006 Apr; 36(1):197-220. PubMed ID: 16605111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
